Get the Stockscreener App
1.63
1.24%
0.02
After Hours:
1.63
Inhibikase Therapeutics Inc stock is traded at $1.63, with a volume of 61,257.
It is up +1.24% in the last 24 hours and up +4.49% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.61
Open:
$1.65
24h Volume:
61,257
Relative Volume:
0.53
Market Cap:
$121.46M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.5208
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
+0.62%
1M Performance:
+4.49%
6M Performance:
-21.26%
1Y Performance:
+10.88%
1-Day Range:
$1.5801
$1.67
1-Week Range:
$1.57
$1.75
52-Week Range:
$1.40
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.63 | 119.97M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Has Inhibikase Therapeutics Inc. formed a bullish divergenceJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com
Why Inhibikase Therapeutics Inc. stock is a must watch in 2025Quarterly Trade Summary & AI Forecasted Entry and Exit Points - newser.com
Why Inhibikase Therapeutics Inc. is moving today2025 Pullback Review & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Inhibikase Therapeutics Inc.Earnings Miss & Low Drawdown Trading Techniques - newser.com
Custom watchlist performance reports with Inhibikase Therapeutics Inc.Day Trade & Real-Time Price Movement Reports - newser.com
How to build a custom watchlist for Inhibikase Therapeutics Inc.Swing Trade & Stock Market Timing Techniques - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock could be top winnerWeekly Market Summary & Real-Time Market Sentiment Reports - newser.com
Pattern recognition hints at Inhibikase Therapeutics Inc. upsideAnalyst Upgrade & Free Expert Verified Stock Movement Alerts - newser.com
Published on: 2025-10-12 03:48:12 - newser.com
Using data tools to time your Inhibikase Therapeutics Inc. exitGap Down & Verified Stock Trade Ideas - newser.com
Can trapped investors hope for a rebound in Inhibikase Therapeutics Inc.Sell Signal & Accurate Technical Buy Alerts - newser.com
Will Inhibikase Therapeutics Inc. stock go up soon2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Evaluating Inhibikase Therapeutics Inc. with trendline analysis2025 Fundamental Recap & Precise Trade Entry Recommendations - newser.com
How geopolitical risks impact Inhibikase Therapeutics Inc. (IQT0) stock2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock is a strong analyst pick2025 Short Interest & Daily Profit Focused Screening - newser.com
Is this a good reentry point in Inhibikase Therapeutics Inc.Trade Volume Summary & Free Growth Oriented Trading Recommendations - newser.com
Inhibikase Therapeutics (NASDAQ:IKT) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Inhibikase Therapeutics Inc Stock Analysis and ForecastHigh Dividend Yield Stocks & Breakthrough Profit Margins - earlytimes.in
What drives Inhibikase Therapeutics Inc IQT0 stock priceVolume Analysis Techniques & Free Explosive Trading Growth - earlytimes.in
Inhibikase Therapeutics Inc. stock outlook for YEARQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
Market reaction to Inhibikase Therapeutics Inc.’s recent news2025 Market Outlook & Fast Entry and Exit Trade Plans - newser.com
What MACD and RSI say about Inhibikase Therapeutics Inc.2025 Retail Activity & Safe Entry Point Alerts - newser.com
Leading vs lagging indicators on Inhibikase Therapeutics Inc. performance2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Inhibikase Therapeutics (NYSE:IKT) vs. LadRx (OTCMKTS:CYTR) Critical Contrast - Defense World
Has Inhibikase Therapeutics Inc. found a price floorPortfolio Return Summary & Short-Term Trading Alerts - newser.com
Using flow based indicators on Inhibikase Therapeutics Inc.CEO Change & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-10-03 06:03:22 - newser.com
Heatmap analysis for Inhibikase Therapeutics Inc. and competitorsMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com
How to monitor Inhibikase Therapeutics Inc. with trend dashboardsPortfolio Profit Report & Free Community Consensus Stock Picks - newser.com
How to interpret RSI for Inhibikase Therapeutics Inc. stockInflation Watch & Low Risk High Win Rate Stock Picks - newser.com
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):